Facebook Pixel

ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)

GRACEcast Lung Cancer Audio
GRACEcast Lung Cancer Audio

Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

GRACEcast Lung Cancer Audio
Not playing